Edesa Biotech and FDA Agree on Primary Endpoint for Phase 3 ARDS Drug Study
- ByInvesting.com-
28-day survival will be evaluated in ARDS patients hospitalized with Covid-19Updated protocol approved by study's ethics committeeCompany exploring pathways for treating general...